220 research outputs found

    Rabdomiólise como efeito adverso ao uso de estatinas: uma revisão bibliográfica

    Get PDF
    Introdução: Dentre os sintomas musculares associados às estatinas (SMAE), a rabdomiólise é, frequentemente, a manifestação de pior prognóstico. Apesar de ser considerada rara, essa condição incorre em um alto nível de mortalidade e possui importante correlação com o tratamento das dislipidemias, já que as estatinas são medicamentos utilizados para essa comorbidade. Logo, o tema abordado tem demonstrado importância na prática clínica e na abordagem farmacológica. Objetivo: Realizar uma revisão bibliográfica acerca dos fatores de risco, manifestações clínicas, métodos diagnósticos e manejo da rabdomiólise induzida por estatinas. Metodologia: Revisão da literatura de caráter analítico e descritivo, seguimos parcialmente a metodologia PRISMA para catalogação dos resultados, sendo selecionados 91 artigos científicos dos quais apenas 44 literaturas foram incluídas na presente revisão. Os artigos foram selecionados a partir das bases de dados Literatura Latino-Americana e do Caribe em Ciências da Saúde (LILACS), Scientific Eletronic Library Online (SCIELO) e National Library of Medicine (PUBMED). Resultado: A rabdomiólise, como reação colateral das estatinas, está bem documentada na literatura. Verifica-se que é uma condição rara e a mais letal das miopatias induzidas por estatinas, já que diversos fatores endógenos e exógenos atuam como potenciais aditivos ao risco de desenvolvimento dessa condição. O diagnóstico é essencialmente baseado nos níveis de Creatinofosfoquinase (CPK) e na sintomatologia adjacente, especialmente a Insuficiência Renal Aguda (IRA). O manejo terapêutico baseia-se na retirada da estatina, suporte clínico e monitoração. Conclusão: A rabdomiólise é uma condição rara, porém de grande relevância clínica por conta de suas graves repercussões. Sua relação com o uso de estatinas deve ser considerada quando a clínica for sugestiva, principalmente na presença de fatores de risco. A informação aos pacientes a respeito dos riscos envolvidos na terapia de estatinas pode ajudar na identificação da miopatia precocemente. Na presença de sintomas, o manejo é baseado na descontinuação do medicamento associado a medidas de suporte clínico. Além disso, deve-se considerar os diagnósticos diferenciais nos casos de não resolução.&nbsp

    Valoração econômica dos benefícios ambientais percebidos pela população da bacia do Educandos provenientes do PROSAMIM Economic valuation of environmental benefits perceived by the Educandos basin population proceeding from PROSAMIM

    No full text
    A poluição ambiental observada ao longo de anos nos igarapés de Manaus (Amazonas-Brasil), associado ao processo de degradação social da população que vive nessas áreas foi o que motivou a concepção do Programa Social e Ambiental dos Igarapés de Manaus PROSAMIM. O Programa busca a recuperação ambiental dos igarapés e a melhoria social das famílias que vivem em situação de risco nas margens. O objetivo principal da pesquisa consistiu em avaliar economicamente os benefícios ambientais percebidos pela população da bacia do Educandos provenientes do PROSAMIM, usando o Método de Valoração Contingente MVC para estimar a disposição a pagar das pessoas pela melhoria ambiental obtida. Foi estimado um tamanho de amostra correspondente a 1.070 questionários, levando em conta um erro de 3% e um nível de significância de 5%. Concluiu-se que a disposição a pagar mensal das pessoas é R13,73eovalorecono^micototalparaamelhoriaambientalrelativaaˋexecuc\ca~odoPROSAMIMeˊR13,73 e o valor econômico total para a melhoria ambiental relativa à execução do PROSAMIM é R 46.325.074,92 por ano. Analisando a influência de variáveis socioeconômicas na probabilidade de aceitar pagar por benefícios ambientais foi observado que somente o nível de renda apresenta significância estatística e o coeficiente angular positivo da variável, indica que a probabilidade de aceitar pagar o valor sugerido é maior em pessoas que têm o nível de renda mais alto. Finalmente, pode ser concluído que as ações do PROSAMIM têm gerado melhorias significantes para a população da cidade de Manaus, tanto do ponto de vista social quanto ambiental.<br>The environmental pollution observed down through the years in the streams of Manaus, linked to the process of social degradation on the populations which live in these areas was the motive for conceiving PROSAMIM - Programa Social e Ambiental dos Igarapés de Manaus. The Program seeks the environmental recuperation of streams and the social improvement of families that live a risk situation on the stream banks. The main target of this research consists in the economical evaluation of environmental benefits perceived by the population in the Educandos basin proceeding from PROSAMIM, using the Contingent Valuation Method - CVM to estimate individual willingness to pay for the environmental improvement. We estimated a sample size corresponding to 1,070 questionnaires, taking into account an error of 3% and significance level of 5%. In accordance with the results obtained, we concluded that the people were willing to pay R13.73permonthtowardimplementingthePROSAMIM,foranannualtotalofR 13.73 per month toward implementing the PROSAMIM, for an annual total of R46,325,074.92 per year. Analyzing the influence of socioeconomic variables on the acceptance probability of paying for environmental benefits, we concluded that the probability was greater among those with a higher income. We also concluded that, the actions of PROSAMIM have generated significant improvements for the population of Manaus from the environmental as well as the social point of view

    30-Day Morbidity and Mortality of Bariatric Surgery During the COVID-19 Pandemic: a Multinational Cohort Study of 7704 Patients from 42 Countries.

    No full text
    BACKGROUND There are data on the safety of cancer surgery and the efficacy of preventive strategies on the prevention of postoperative symptomatic COVID-19 in these patients. But there is little such data for any elective surgery. The main objectives of this study were to examine the safety of bariatric surgery (BS) during the coronavirus disease 2019 (COVID-19) pandemic and to determine the efficacy of perioperative COVID-19 protective strategies on postoperative symptomatic COVID-19 rates. METHODS We conducted an international cohort study to determine all-cause and COVID-19-specific 30-day morbidity and mortality of BS performed between 01/05/2020 and 31/10/2020. RESULTS Four hundred ninety-nine surgeons from 185 centres in 42 countries provided data on 7704 patients. Elective primary BS (n = 7084) was associated with a 30-day morbidity of 6.76% (n = 479) and a 30-day mortality of 0.14% (n = 10). Emergency BS, revisional BS, insulin-treated type 2 diabetes, and untreated obstructive sleep apnoea were associated with increased complications on multivariable analysis. Forty-three patients developed symptomatic COVID-19 postoperatively, with a higher risk in non-whites. Preoperative self-isolation, preoperative testing for SARS-CoV-2, and surgery in institutions not concurrently treating COVID-19 patients did not reduce the incidence of postoperative COVID-19. Postoperative symptomatic COVID-19 was more likely if the surgery was performed during a COVID-19 peak in that country. CONCLUSIONS BS can be performed safely during the COVID-19 pandemic with appropriate perioperative protocols. There was no relationship between preoperative testing for COVID-19 and self-isolation with symptomatic postoperative COVID-19. The risk of postoperative COVID-19 risk was greater in non-whites or if BS was performed during a local peak

    Safety of Bariatric Surgery in ≥ 65-Year-Old Patients During the COVID-19 Pandemic

    No full text
    Background Age &gt;= 65 years is regarded as a relative contraindication for bariatric surgery. Advanced age is also a recognised risk factor for adverse outcomes with Coronavirus Disease-2019 (COVID-19) which continues to wreak havoc on global populations. This study aimed to assess the safety of bariatric surgery (BS) in this particular age group during the COVID-19 pandemic in comparison with the younger cohort.Methods We conducted a prospective international study of patients who underwent BS between 1/05/2020 and 31/10/2020. Patients were divided into two groups - patients &gt;= 65-years-old (Group I) and patients &lt; 65-years-old (Group II). The two groups were compared for 30-day morbidity and mortality.Results There were 149 patients in Group 1 and 6923 patients in Group II. The mean age, preoperative weight, and BMI were 67.6 +/- 2.5 years, 119.5 +/- 24.5 kg, and 43 +/- 7 in Group I and 39.8 +/- 11.3 years, 117.7 +/- 20.4 kg, and 43.7 +/- 7 in Group II, respectively. Approximately, 95% of patients in Group 1 had at least one co-morbidity compared to 68% of patients in Group 2 (p = &lt; 0.001). The 30-day morbidity was significantly higher in Group I ( 11.4%) compared to Group II (6.6%) (p = 0.022). However, the 30-day mortality and COVID-19 infection rates were not significantly different between the two groups.Conclusions Bariatric surgery during the COVID-19 pandemic is associated with a higher complication rate in those &gt;= 65 years of age compared to those &lt; 65 years old. However, the mortality and postoperative COVID-19 infection rates are not significantly different between the two groups

    Effect of BMI on safety of bariatric surgery during the COVID-19 pandemic, procedure choice, and safety protocols - An analysis from the GENEVA Study

    No full text
    Background: It has been suggested that patients with a Body Mass Index (BMI) of &gt; 60 kg/m2 should be offered expedited Bariatric Surgery (BS) during the Coronavirus Disease-2019 (COVID-19) pandemic. The main objective of this study was to assess the safety of this approach. Methods: We conducted a global study of patients who underwent BS between 1/05/2020 and 31/10/2020. Patients were divided into three groups according to their preoperative BMI -Group I (BMI &lt; 50 kg/m2), Group II (BMI 50-60 kg/m2), and Group III (BMI &gt; 60 kg/m2). The effect of preoperative BMI on 30-day morbidity and mortality, procedure choice, COVID-19 specific safety protocols, and comorbidities was assessed. Results: This study included 7084 patients (5197;73.4 % females). The mean preoperative weight and BMI were 119.49 &amp; PLUSMN; 24.4 Kgs and 43.03 &amp; PLUSMN; 6.9 Kg/m2, respectively. Group I included 6024 (85 %) patients, whereas Groups II and III included 905 (13 %) and 155 (2 %) patients, respectively.The 30-day mortality rate was higher in Group III (p = 0.001). The complication rate and COVID-19 infection were not different. Comorbidities were significantly more likely in Group III (p = &lt; 0.001). A significantly higher proportion of patients in group III received Sleeve Gastrectomy or One Anastomosis Gastric Bypass compared to other groups. Patients with a BMI of &gt; 70 kg/m2 had a 30-day mortality of 7.7 % (2/26). None of these patients underwent a Roux-en-Y Gastric Bypass. Conclusion: The 30-day mortality rate was significantly higher in patients with BMI &gt; 60 kg/m2. There was, however, no significant difference in complications rates in different BMI groups, probably due to differences in procedure selection

    NEOTROPICAL XENARTHRANS: a data set of occurrence of xenarthran species in the Neotropics

    No full text
    Xenarthrans—anteaters, sloths, and armadillos—have essential functions for ecosystem maintenance, such as insect control and nutrient cycling, playing key roles as ecosystem engineers. Because of habitat loss and fragmentation, hunting pressure, and conflicts with domestic dogs, these species have been threatened locally, regionally, or even across their full distribution ranges. The Neotropics harbor 21 species of armadillos, 10 anteaters, and 6 sloths. Our data set includes the families Chlamyphoridae (13), Dasypodidae (7), Myrmecophagidae (3), Bradypodidae (4), and Megalonychidae (2). We have no occurrence data on Dasypus pilosus (Dasypodidae). Regarding Cyclopedidae, until recently, only one species was recognized, but new genetic studies have revealed that the group is represented by seven species. In this data paper, we compiled a total of 42,528 records of 31 species, represented by occurrence and quantitative data, totaling 24,847 unique georeferenced records. The geographic range is from the southern United States, Mexico, and Caribbean countries at the northern portion of the Neotropics, to the austral distribution in Argentina, Paraguay, Chile, and Uruguay. Regarding anteaters, Myrmecophaga tridactyla has the most records (n = 5,941), and Cyclopes sp. have the fewest (n = 240). The armadillo species with the most data is Dasypus novemcinctus (n = 11,588), and the fewest data are recorded for Calyptophractus retusus (n = 33). With regard to sloth species, Bradypus variegatus has the most records (n = 962), and Bradypus pygmaeus has the fewest (n = 12). Our main objective with Neotropical Xenarthrans is to make occurrence and quantitative data available to facilitate more ecological research, particularly if we integrate the xenarthran data with other data sets of Neotropical Series that will become available very soon (i.e., Neotropical Carnivores, Neotropical Invasive Mammals, and Neotropical Hunters and Dogs). Therefore, studies on trophic cascades, hunting pressure, habitat loss, fragmentation effects, species invasion, and climate change effects will be possible with the Neotropical Xenarthrans data set. Please cite this data paper when using its data in publications. We also request that researchers and teachers inform us of how they are using these data

    30-Day morbidity and mortality of bariatric metabolic surgery in adolescence during the COVID-19 pandemic – The GENEVA study

    No full text
    Background: Metabolic and bariatric surgery (MBS) is an effective treatment for adolescents with severe obesity. Objectives: This study examined the safety of MBS in adolescents during the coronavirus disease 2019 (COVID-19) pandemic. Methods: This was a global, multicentre and observational cohort study of MBS performed between May 01, 2020, and October 10,2020, in 68 centres from 24 countries. Data collection included in-hospital and 30-day COVID-19 and surgery-specific morbidity/mortality. Results: One hundred and seventy adolescent patients (mean age: 17.75 ± 1.30 years), mostly females (n&nbsp;=&nbsp;122, 71.8%), underwent MBS during the study period. The mean pre-operative weight and body mass index were 122.16 ± 15.92 kg and 43.7&nbsp;± 7.11 kg/m2, respectively. Although majority of patients had pre-operative testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (n&nbsp;=&nbsp;146; 85.9%), only 42.4% (n&nbsp;=&nbsp;72) of the patients were asked to self-isolate pre-operatively. Two patients developed symptomatic SARS-CoV-2 infection post-operatively (1.2%). The overall complication rate was 5.3% (n&nbsp;=&nbsp;9). There was no mortality in this cohort. Conclusions: MBS in adolescents with obesity is safe during the COVID-19 pandemic when performed within the context of local precautionary procedures (such as pre-operative testing). The 30-day morbidity rates were similar to those reported pre-pandemic. These data will help facilitate the safe re-introduction of MBS services for this group of patients

    Management of coronary disease in patients with advanced kidney disease

    No full text
    BACKGROUND Clinical trials that have assessed the effect of revascularization in patients with stable coronary disease have routinely excluded those with advanced chronic kidney disease. METHODS We randomly assigned 777 patients with advanced kidney disease and moderate or severe ischemia on stress testing to be treated with an initial invasive strategy consisting of coronary angiography and revascularization (if appropriate) added to medical therapy or an initial conservative strategy consisting of medical therapy alone and angiography reserved for those in whom medical therapy had failed. The primary outcome was a composite of death or nonfatal myocardial infarction. A key secondary outcome was a composite of death, nonfatal myocardial infarction, or hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest. RESULTS At a median follow-up of 2.2 years, a primary outcome event had occurred in 123 patients in the invasive-strategy group and in 129 patients in the conservative-strategy group (estimated 3-year event rate, 36.4% vs. 36.7%; adjusted hazard ratio, 1.01; 95% confidence interval [CI], 0.79 to 1.29; P=0.95). Results for the key secondary outcome were similar (38.5% vs. 39.7%; hazard ratio, 1.01; 95% CI, 0.79 to 1.29). The invasive strategy was associated with a higher incidence of stroke than the conservative strategy (hazard ratio, 3.76; 95% CI, 1.52 to 9.32; P=0.004) and with a higher incidence of death or initiation of dialysis (hazard ratio, 1.48; 95% CI, 1.04 to 2.11; P=0.03). CONCLUSIONS Among patients with stable coronary disease, advanced chronic kidney disease, and moderate or severe ischemia, we did not find evidence that an initial invasive strategy, as compared with an initial conservative strategy, reduced the risk of death or nonfatal myocardial infarction

    Health status after invasive or conservative care in coronary and advanced kidney disease

    No full text
    BACKGROUND In the ISCHEMIA-CKD trial, the primary analysis showed no significant difference in the risk of death or myocardial infarction with initial angiography and revascularization plus guideline-based medical therapy (invasive strategy) as compared with guideline-based medical therapy alone (conservative strategy) in participants with stable ischemic heart disease, moderate or severe ischemia, and advanced chronic kidney disease (an estimated glomerular filtration rate of &lt;30 ml per minute per 1.73 m2 or receipt of dialysis). A secondary objective of the trial was to assess angina-related health status. METHODS We assessed health status with the Seattle Angina Questionnaire (SAQ) before randomization and at 1.5, 3, and 6 months and every 6 months thereafter. The primary outcome of this analysis was the SAQ Summary score (ranging from 0 to 100, with higher scores indicating less frequent angina and better function and quality of life). Mixed-effects cumulative probability models within a Bayesian framework were used to estimate the treatment effect with the invasive strategy. RESULTS Health status was assessed in 705 of 777 participants. Nearly half the participants (49%) had had no angina during the month before randomization. At 3 months, the estimated mean difference between the invasive-strategy group and the conservative-strategy group in the SAQ Summary score was 2.1 points (95% credible interval, 120.4 to 4.6), a result that favored the invasive strategy. The mean difference in score at 3 months was largest among participants with daily or weekly angina at baseline (10.1 points; 95% credible interval, 0.0 to 19.9), smaller among those with monthly angina at baseline (2.2 points; 95% credible interval, 122.0 to 6.2), and nearly absent among those without angina at baseline (0.6 points; 95% credible interval, 121.9 to 3.3). By 6 months, the between-group difference in the overall trial population was attenuated (0.5 points; 95% credible interval, 122.2 to 3.4). CONCLUSIONS Participants with stable ischemic heart disease, moderate or severe ischemia, and advanced chronic kidney disease did not have substantial or sustained benefits with regard to angina-related health status with an initially invasive strategy as compared with a conservative strategy
    corecore